Andrew Wells
PROFESSOR
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (26)
Table S7: Number of TARGET samples with WGS and SCNA events per cancer identified by GISTIC, Table S8: Differential expression of genes in samples with and without SCNA, Table S9: Number of samples with SVs in lncRNAs
Year:
2025
Table S15: Data integration using multi-dimensional analysis to prioritize functional lncRNAs in each cancer, Table S16: Prioritized lncRNAs and predicted lncRNA target genes and pathways in NBL, Table S17: GSEA Analysis: MSigDB Hallmarks enriched across genes impacted by siTBX2-AS1 or siTBX2 treatment in NLF
Year:
2025
Table S10: Statistics for input and output variables of lncMod analysis (xls file), Table S11: Significantly dysregulated lncMod triplets, Table S12: lncRNA TF associations ranked by # target genes
Year:
2025
Table S1: TARGET clinical sample and RNA-sequencing characteristics, Table S2: Genomic loci for lncRNA and protein coding genes in this study, Table S3: Number and types of genes expressed per cancer
Year:
2025
Table S4: Top 10 expressed lncRNAs across TARGET cancers and GTEx tissues, Table S5: Tissue specificity index (tau score) annotation per gene, Table S6: Validation of tissue specific lncRNAs based on tau score analysis in alternate NBL datasets
Year:
2025
Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact cis -regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk. We localized risk variants from 15 autoimmune GWAS to cRE active during TCR-CD28 co-stimulation of naïve human CD4+ T cells. To characterize how dynamic changes in gene expression correlate with cRE activity, we measured transcript levels, chromatin accessibility, and promoter–cRE contacts across three phases of naive CD4+ T cell activation using RNA-seq, ATAC-seq, and HiC. We identified ~1200 protein-coding genes physically connected to accessible disease-associated variants at 423 GWAS signals, at least one-third of which are dynamically regulated by activation. From these maps, we functionally validated a novel stretch of evolutionarily conserved intergenic enhancers whose activity is required for activation-induced IL2 gene expression in human and mouse, and is influenced by autoimmune-associated genetic variation. The set of genes implicated by this approach are enriched for genes controlling CD4+ T cell function and genes involved in human inborn errors of immunity, and we pharmacologically validated eight implicated genes as novel regulators of T cell activation. These studies directly show how autoimmune variants and the genes they regulate influence processes involved in CD4+ T cell proliferation and activation.
Year:
2024
Table S1: TARGET clinical sample and RNA-sequencing characteristics, Table S2: Genomic loci for lncRNA and protein coding genes in this study, Table S3: Number and types of genes expressed per cancer
Year:
2024
Table S4: Top 10 expressed lncRNAs across TARGET cancers and GTEx tissues, Table S5: Tissue specificity index (tau score) annotation per gene, Table S6: Validation of tissue specific lncRNAs based on tau score analysis in alternate NBL datasets
Year:
2024
Table S15: Data integration using multi-dimensional analysis to prioritize functional lncRNAs in each cancer, Table S16: Prioritized lncRNAs and predicted lncRNA target genes and pathways in NBL, Table S17: GSEA Analysis: MSigDB Hallmarks enriched across genes impacted by siTBX2-AS1 or siTBX2 treatment in NLF
Year:
2024
Table S10: Statistics for input and output variables of lncMod analysis (xls file), Table S11: Significantly dysregulated lncMod triplets, Table S12: lncRNA TF associations ranked by # target genes
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (25)
Sharon Diskin
Associate Professor
University of Pennsylvania
Struan Grant
Professor of Genetics and Pediatrics
University of Pennsylvania
Rachel Kember
Research Assistant Professor
University of Pennsylvania
Eugene Katsevich
Assistant Professor
University of Pennsylvania
Paul M Titchenell
University of Pennsylvania
Laura Cook
Senior Research Fellow and Group Leader
University of Melbourne
Kurt Hankenson
University of Michigan
Elizabeth J Perlman
Ann and Robert H Lurie Children's Hospital of Chicago
Yadav Wagley
University of Michigan Medical School
Henry Kranzler
Professor
University of Pennsylvania
Babette S Zemel
Professor
Children's Hospital of Philadelphia
Soheil Meshinchi
Fred Hutchinson Cancer Research Center
Megan Levings
Professor
The University of British Columbia
Michael Zuscik
Mack Clayton Professor, Vice Chair of Research, Director of the Colorado Program for Musculoskeletal Research
University of Colorado Anschutz Medical Campus
Benjamin F. Voight
Professor
University of Pennsylvania
Wayne Hancock
Professor
University of Pennsylvania
John Maris
PI
University of Pennsylvania
Jaclyn Welles
Research Assistant Professor
Northeast Ohio Medical University
Wenli Yang
Research Assistant Professor
University of Pennsylvania
Jinghui Zhang
Professor
St. Jude Children's Research Hospital
Klaus Kaestner
Professor
University of Pennsylvania
Alessandra Chesi
Assistant Professor
University of Pennsylvania
Cheryl Ackert-Bicknell
Professor
University of Colorado Hospital
Joan M. O’Brien
University of Pennsylvania
Patrick Seale
Associate Professor
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.